Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Analgesics

Cytarabine

Venetoclax

Mitoxantrone

Lenograstim

Cladribine

Navitoclax

Antimetabolites

Antiviral Agents

Immunosuppressive Agents

Immunologic Factors

Enzyme Inhibitors

Adjuvants, Immunologic

Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.

This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.

The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.

Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.

This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and granulocyte colony-stimulating factor (G-CSF).

This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.

Navitoclax Dose Level -1

Navitoclax Dose Level 0

Navitoclax Dose Level 1

Navitoclax Dose Level 2

Venetoclax Dose Level -1

Venetoclax Dose Levels 0 to 2

Cytarabine (Cladribine Low Dose Cytarabine Backbone)

Cytarabine (CLAG-M Backbone)

Granulocyte Colony-Stimulating Factor

Medical College of Wisconsin Cancer Center Clinical Trials Office

Guru Subramanian Guru Murthy, MD, MS

This is an open-label phase I study designed to evaluate the safety of venetoclax-navitoclax with cladribine-based salvage therapy.

The primary objective of the study is to determine a maximum-tolerated dose (MTD) combination of venetoclax-navitoclax with cladribine-based salvage therapy. Subjects will be entered sequentially to each dose level. For each dose level, if none of the first three subjects at that level experiences a dose-limiting toxicity (DLT), new subjects may be entered at the next higher dose level. If one of three subjects experience a DLT, up to three more subjects are to be treated at that same dose level. If none of the additional three subjects at that dose level experiences a DLT, new subjects may be entered at the next higher dose level. However, if one or more of the additional three subjects experience a DLT, then no further subjects are to be started at that dose level and either de-escalate one level or if the preceding dose is already completed then that dose is the MTD. The MTD will be defined as the highest dose level at which none of the first three treated subjects, or no more than one of the first six treated subjects, experiences a DLT.

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The dose identified in this trial that will be used in future clinical trials.

Medical College of Wisconsin

Assistant Professor

Spots Global Cancer Trial Database for cytarabine (cladribine low dose cytarabine backbone)